No Detail Found!

Population pharmacokinetics of linezolid among post-operative patients: Implications for dosing strategies

Author(s)
Annum Maha Institute of Pharmaceutical Sciences, University of Veterinary and Animal Sciences,Lahore,Pakistan
Mohsin Ali Department of Pharmacy Practice, Faculty of Pharmaceutical Sciences, Govt. College University Faisalabad,,Pakistan
Hajira Bilal Faculty of Pharmacy and Pharmaceutical Sciences, Monash University,Parkville VIC, 3052,Australia
Muhammad Imran Khokhar Gujranwala Medical College, DHQ Teaching Hospital Gujranwala,,Pakistan
Abdul Muqeet Khan Quality Operational Laboratory, University of Veterinary and Animal Sciences, Lahore, Pakistan
Rabia Khokhar Institute of Pharmaceutical Sciences, University of Veterinary and Animal Sciences,Lahore,Pakistan
Ijaz Alvi Epileptic drug research (Pharmacology), Bahauddin Zakariya University,Multan,Pakistan
Mamoona Tariq School of Pharmaceutical Sciences, Shanghai Jiao Tong University, China
Mian Waqar Mustafa Department of Pharmacy, Forman Christian College University,Lahore,Pakistan
Walaa F Alsanie Department of Clinical Laboratory Sciences, Faculty of Applied Medical Sciences, Taif University,Taif,Saudi Arabia
Abdulhakeem S Alamri Department of Clinical Laboratory Sciences, Faculty of Applied Medical Sciences, Taif University,Taif,Saudi Arabia
Majid Alhomrani Department of Clinical Laboratory Sciences, Faculty of Applied Medical Sciences, Taif University,Taif,Saudi Arabia
Muhammad Usman Institute of Pharmaceutical Sciences, University of Veterinary and Animal Sciences,Lahore,Pakistan
Abstract
Linezolid is a synthetic antibiotic and produces its antibacterial effect by inhibiting protein synthesis. It is used to treat life-threatening infections caused by MRSA and VRE. Linezolid clearance occurs through both the renal and hepatic routes. The identification of factors associated with linezolid clearance is required in Pakistani patients. A total of 215 samples from 59 post-operative patients were collected from a tertiary care hospital after a first dose of linezolid. The data was used to develop a population pharmacokinetic (popPK) model by using NONMEM® software. Analysis of the available covariates on pharmacokinetic parameters of linezolid was performed by using stepwise covariate modeling approach, A one-compartment model described the popPK and the value for linezolid clearance (CL) was 3.72 L/h while that of volume of distribution (Vd) was 36.9 L. The interindividual variability on linezolid CL was 36.5%. During stepwise covariate analysis, creatinine clearance (CRCL) was proved to be a significant covariate on CL. This is concluded that the clearance of linezolid is influenced by the renal status of patients and there is a dire need for dose optimization of linezolid in Pakistani patients based on renal status in order to avoid toxicity and adverse drug effects.
Publication Details
Page(s) 291-298
Published Journal: Pakistan Journal of Pharmaceutical Sciences, Volume: 38, Issue: 1, Year: 2025

Request the full text from PASTIC

Keywords
Linezolid, NONMEM®, population pharmacokinetics
References
Abdelsalam Elshenawy R,Umaru N,Aslanpour Z N .2023 .WHO AWaRe classification for antibiotic stewardship: Tackling antimicrobial resistance - a descriptive study from an English NHS Foundation Trust prior to and during the COVID-19 pandemic. , 14 : 1298858.
Abdelwahab MT,Wasserman S,Brust JCM,Dheda K,Wiesner L,Gandhi NR,Warren RM,Sirgel FA,Meintjes G,Maartens G,Denti P .2021 .Linezolid population pharmacokinetics in South African adults with drug-resistant tuberculosis. Antimicrob, 65(12) : e0138121.
Abe S,Chiba K,Cirincione B,Grasela TH,Ito K,Suwa T .2009 .Population pharmacokinetic analysis of 296 linezolid in patients with infectious disease: Application to lower body weight and elderly patients. J. Clin. Pharmacol, 49(9) : 1071-1078.
Alghamdi WA,Al-Shaer MH,An G,Alsultan A,Kipiani M,Barbakadze K,Mikiashvili L,Ashkin D,Griffith DE,Cegielski JP,Kempker RR,Peloquin CA .2020 .Population pharmacokinetics of linezolid in tuberculosis patients: Dosing regimen simulation and target attainment analysis. Antimicrob. Agents Chemother, 64(10) : e01174-01120.
Bai AD,McKenna S,Wise H,Loeb M,Gill SS M .2022 .Safety profile of linezolid in older adults with renal impairment: A population-based retrospective cohort study. Open Forum Infect. Dis., 9(12) : ofac669.
Boak LM,Rayner CR,Grayson ML,Paterson DL,Spelman D,Khumra S,Capitano B,Forrest A,Li J,Nation RL .2014 .Clinical population pharmacokinetics and toxicodynamics of linezolid. , 58(4) : 2334-2343.
Brier ME,Stalker DJ,Aronoff GR,Batts DH,Ryan KK,O'Grady M,Hopkins NK,Jungbluth GL .2003 .Pharmacokinetics of linezolid in subjects with renal dysfunction. Antimicrob, 47(9) : 2775-2780.
Caroline P and Linezolid J .2001 .A review of its use in the management of serious gram-positive infections. , 63(19) : 2126-2126.
Cattaneo D,Orlando G,Cozzi V,Cordier L,Baldelli S,Merli S,Fucile S,Gulisano C,Rizzardini G,Clementi EJIjoaa G .2013 .Linezolid plasma concentrations and occurrence of drug-related haematological toxicity in patients with gram-positive infections. Int. J. Antimicrob. Agents, 41(6) : 586-589.
Clemett D and Markham A .2000 .. Linezolid. Drugs, 59(4) : 815-827.
Cockcroft DW,Gault MH .1976 .Prediction of creatinine clearance from serum creatinine. Nephron, 16(1) : 31-41.
Dong H-Y J,Chen L-H,Wang T-T,Zhao Y-R,Dong Y-L .2014 .Therapeutic drug monitoring and receiver operating characteristic curve prediction may reduce the development of linezolid-associated thrombocytopenia in critically ill patients. Eur. J. Clin. Microbiol, 33(6) : 1029-1035.
Dosne AG,Bergstrand M,Karlsson MO M .2016 .A strategy for residual error modeling incorporating scedasticity of variance and distribution shape. J. Pharmacokinet. Pharmacodyn., 43(2) : 137-151.
Dryden MS .2011 .Linezolid pharmacokinetics and pharmacodynamics in clinical treatment. J. Antimicrob. Chemother., 66(suppl) : 7-15.
Eekhout I,Heymans MW .2017 .Methods for significance testing of categorical covariates in logistic regression models after multiple imputation: Power and applicability analysis. BMC Med, 17(1) : 129.
Goodyear MD,Krleza-Jeric K,Lemmens T .2007 .. The declaration of Helsinki. BMJ, 335(7621) : 624-625.
Ippolito JA,Kanyo ZF,Wang D,Franceschi FJ,Moore PB,Steitz TA,Duffy EM .2008 .Crystal structure of the oxazolidinone antibiotic linezolid bound to the 50S ribosomal subunit. J. Med, 51(12) : 3353-3356.
Keizer RJ,Van Benten M,Beijnen JH,Schellens JH,Huitema AD .2011 .Pirana and PCluster: A modeling environment and cluster infrastructure for NONMEM. Comput. Methods Programs Biomed. , 101(1) : 72-79.
Keutzer L,Mockeliunas L,Sturkenboom MGG,Bolhuis MS,Akkerman OW,Simonsson USH .2023 .Derivation and clinical utility of safety targets for linezolid-related adverse events in drug-resistant tuberculosis treatment. Pharmaceuticals (Basel), 16(11) : 1-18.
Leon Shargel ABY .2015 .Applied biopharmaceutics and Pharmacokinetics (7th ed. McGraw Hill Education., : .
Li SC,Ye Q,Xu H,Zhang L,Wang Y .2019 .Population pharmacokinetics and dosing optimization of linezolid in pediatric patients. Antimicrob, 63(4) : e02387-02318.
Lindbom L,Ribbing J,Jonsson EN .2004 .Perlspeaks-NONMEM (PsN) - a Perl module for NONMEM related programming. Comput. Methods Programs, 75(2) : 85-94.
Minotti C,Bonadies L,Liberati C,De Pieri M,Giaquinto C,Baraldi E,Donà D .2022 .Enteral linezolid as an effective option to treat an extremely preterm infant with bacillus cereus sepsis. Children (Basel), 9(3) : 415.
Mockeliunas L,Keutzer L,Sturkenboom MGG,Bolhuis MS,Hulskotte LMG,Akkerman OW,Simonsson USH .2022 .Model-informed precision dosing of linezolid in patients with drug-resistant tuberculosis. Pharmaceutics, 14(4) : 753.
Paal M,Zoller M,Schuster C,Vogeser M,Schütze G. .2018 .Simultaneous quantification of cefepime, meropenem, ciprofloxacin, moxifloxacin, linezolid and piperacillin in human serum using an isotope-dilution HPLC-MS/MS method. J. Pharm. Biomed. Anal., 152 : 102-110.
Qin Y,Zhang LL,Ye YR,Chen YT,Jiao Z. .2022 .Parametric population pharmacokinetics of linezolid: A systematic review. Br. J. Clin. Pharmacol, 88(9) : 4043-4066.
Rabon AD,Fisher JP,MacVane SHJAoP JP .2018 .Incidence and risk factors for development of thrombocytopenia in patients treated with linezolid for 7 days or greater. , 52(11) : 1162-1164.
Rao GG,Konicki R,Cattaneo D,Alffenaar J-W,Marriott DJ,Neely M .2020 .Therapeutic drug monitoring can improve linezolid dosing regimens in current clinical practice: A review of linezolid pharmacokinetics and pharmacodynamics. , 42(1) : 83-92.
Reddy KK,Rao SM,Reddy GO,Suresh T,Babu JM,Dubey P,Vyas K P .2002 .Isolation and characterization of process-related impurities in linezolid. J. Pharm. Biomed. Anal., 30(3) : 635-642.
Roger C,Muller L,Wallis S,Louart B,Saissi G,Lipman J,Lefrant J,Roberts JA .2016 .Population pharmacokinetics of linezolid in critically ill patients on renal replacement therapy: Comparison of equal doses in continuous venovenous haemofiltration and continuous venovenous haemodiafiltration. J. Antimicrob. Chemother., 71(2) : 464-470.
Sasaki T,Takane H,Ogawa K,Isagawa S,Hirota T,Higuchi S,Horii T,Otsubo K,Ieiri I .2011 .Population Pharmacokinetic and pharmacodynamic analysis of linezolid and a hematologic side effect, thrombocytopenia in Japanese patients. , 55(5) : 1867-1873.
Sazdanovic P,Jankovic SM,Kostic M,Dimitrijevic A,Stefanovic S A .2016 .Pharmacokinetics of linezolid in critically ill patients. Expert Opin. Drug Metab. Toxicol., 12(6) : 595-600.
Soraluce A,Barrasa H,Asín-Prieto E,Sánchez-Izquierdo JÁ,Maynar J,Isla A,Rodríguez-Gascón A .2020 .Novel population pharmacokinetic model for linezolid in critically ill patients and evaluation of the adequacy of the current dosing recommendation. Pharmaceutics, 12(1) : 54.
Swoboda S,Ober MC,Lichtenstern C,Saleh S,Schwenger V,Sonntag H-G,Haefeli WE,Hempel G,Hoppe-Tichy T,Weigand MA .2010 .Pharmacokinetics of linezolid in septic patients with and without extended dialysis. Clinical Trial, 66(3) : 291-298.
Tsuji Y,Mizoguchi A,Sadoh S,Hiraki Y,Matsumoto K,Morita K,Kobayashi T,Kamimura H,Karube Y .2011 .Thrombocytopenia and anemia caused by a persistent high linezolid concentration in patients with renal dysfunction. J. Infect. Chemother., 17(1) : 70-75.
Tsuji Y,Yukawa E,Hiraki Y,Matsumoto K,Mizoguchi A,Morita K,Kamimura H,Karube Y,To H Y .2013 .Population pharmacokinetic analysis of linezolid in low body weight patients with renal dysfunction. J. Clin. Pharmacol, 53(9) : 967-973.
Vinh DC,Rubinstein E .2009 .Linezolid: A review of safety and tolerability. J. Infect. Chemother., 59 : S59-S74.
Wu F,Zhang XS,Dai Y,Zhou ZY,Zhang CH,Han L,Xu FM,Wang YX,Shi DW,Lin GY,Yu XB,Chen F XB .2022 .Dosage strategy of linezolid according to the trough concentration target and renal function in Chinese critically ill patients. Front, 13 : 844567.
Xie F,Mantzarlis K,Malliotakis P,Koulouras V,Degroote S,Koulenti D,Blot S,Boussery K,Van Bocxlaer K,Colin P .2018 .Pharmacokinetic evaluation of linezolid administered intravenously in obese patients with pneumonia. J. Antimicrob. Chemother., 74(3) : 667-674.
Xu Y,Yang X,Liang P,Qu C .2023 .Linezolid dose adjustment according to therapeutic drug monitoring helps reach the goal concentration in severe patients, and the oldest seniors benefit more. BMC Infect. Dis., 23(1) : 840.
Zhang H,He Y,Davies Forsman L,Paues J,Werngren J,Niward K,Schön T,Bruchfeld J,Alffenaar JW,Hu Y .2023 .Population pharmacokinetics and dose evaluations of linezolid in the treatment of multidrugresistant tuberculosis. Front, 13 : 1032674.
Zhang S-h,Li Z,Zou Y,Yan Y,Xu M,Wang Y,Liu F,Zhang B-K M-z .2020 .Population pharmacokinetics and dosage optimization of linezolid in patients with liver dysfunction. Antimicrob, 64(6) : e00133-00120.
0

Citations

0

Downloads

115

Views